Avicanna (TSE:AVCN) has released an update.
Avicanna Inc., a biopharmaceutical firm specializing in cannabinoid-based products, has been granted a U.S. patent for its innovative self-emulsifying drug delivery system (SEDDS) designed for oral use to treat neuropathic pain. The technology promises improved absorption and stability of cannabinoids, with the company eyeing further clinical applications and patient support in the therapeutic area. Avicanna continues to expand its portfolio, which includes the RHO Phyto medical cannabis formulary and the recently approved pharmaceutical Trunerox™ for seizure adjunct treatment in Colombia.
For further insights into TSE:AVCN stock, check out TipRanks’ Stock Analysis page.
